MX2019014122A - Formulaciones de dosis fija. - Google Patents

Formulaciones de dosis fija.

Info

Publication number
MX2019014122A
MX2019014122A MX2019014122A MX2019014122A MX2019014122A MX 2019014122 A MX2019014122 A MX 2019014122A MX 2019014122 A MX2019014122 A MX 2019014122A MX 2019014122 A MX2019014122 A MX 2019014122A MX 2019014122 A MX2019014122 A MX 2019014122A
Authority
MX
Mexico
Prior art keywords
fixed dose
dose formulations
formulations
compositions
bempedoic acid
Prior art date
Application number
MX2019014122A
Other languages
English (en)
Spanish (es)
Inventor
S Pilgaonkar Pratibha
Abdelnasser Mohamed
S Gandhi Anikumar
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of MX2019014122A publication Critical patent/MX2019014122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019014122A 2017-05-26 2018-05-25 Formulaciones de dosis fija. MX2019014122A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511889P 2017-05-26 2017-05-26
US15/859,279 US20180338922A1 (en) 2017-05-26 2017-12-29 Fixed dose formulations
PCT/US2018/034646 WO2018218147A1 (en) 2017-05-26 2018-05-25 Fixed dose formulations

Publications (1)

Publication Number Publication Date
MX2019014122A true MX2019014122A (es) 2020-02-07

Family

ID=62621055

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014122A MX2019014122A (es) 2017-05-26 2018-05-25 Formulaciones de dosis fija.
MX2023006541A MX2023006541A (es) 2017-05-26 2019-11-26 Formulaciones de dosis fija.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006541A MX2023006541A (es) 2017-05-26 2019-11-26 Formulaciones de dosis fija.

Country Status (16)

Country Link
US (2) US20180338922A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630070A1 (cg-RX-API-DMAC7.html)
JP (3) JP7187488B2 (cg-RX-API-DMAC7.html)
KR (3) KR102830720B1 (cg-RX-API-DMAC7.html)
CN (1) CN110996914A (cg-RX-API-DMAC7.html)
AU (2) AU2018272040A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064895A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003437A1 (cg-RX-API-DMAC7.html)
IL (2) IL270866B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019014122A (cg-RX-API-DMAC7.html)
PH (1) PH12019502782A1 (cg-RX-API-DMAC7.html)
TW (2) TWI798228B (cg-RX-API-DMAC7.html)
UA (1) UA126451C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018218147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201908030B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392182B (es) 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3752133A1 (en) * 2018-02-16 2020-12-23 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
WO2020046836A1 (en) * 2018-08-27 2020-03-05 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
CN112437765A (zh) * 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法
US12528759B2 (en) 2019-10-03 2026-01-20 Synthon B.V. Crystalline forms of bempedoic acid
EP4069668A1 (en) 2019-12-06 2022-10-12 Synthon B.V. Crystalline forms of sodium salt of bempedoic acid
US20230149313A1 (en) * 2020-04-10 2023-05-18 Japan Vam & Poval Co., Ltd. Sustained-release base
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法
WO2021255180A1 (en) 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
EP4401708A1 (en) 2021-09-13 2024-07-24 Synthon B.V. Pharmaceutical composition of bempedoic acid
US20250302750A1 (en) * 2022-05-09 2025-10-02 Renata Pharmaceuticals (Ireland) Ltd Pharmaceutical composition of bempedoic acid
JP7877242B2 (ja) * 2023-02-16 2026-06-22 株式会社三共 遊技機
JP7877241B2 (ja) * 2023-02-16 2026-06-22 株式会社三共 遊技機
WO2026125708A1 (en) 2024-12-12 2026-06-18 Krka, D.D., Novo Mesto Tablets comprising bempedoic acid or bempedoic acid and ezetimibe

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP4438268B2 (ja) * 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
ES2382773T3 (es) * 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
PL2407166T3 (pl) * 2009-03-13 2014-01-31 Toyama Chemical Co Ltd Tabletka i granulowany proszek zawierające 6-fluoro-3-hydroksy-2-pirazynokarboksamid
PL2459175T3 (pl) * 2009-07-28 2018-04-30 Egis Gyógyszergyár Zrt. Nowy proces granulowania i otrzymany w ten sposób granulat
CN101926756B (zh) * 2010-08-12 2012-01-18 北京赛科药业有限责任公司 一种氯吡格雷或其药学上可接受盐的固体制剂
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
US10137093B2 (en) * 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
CA2933202C (en) * 2014-01-21 2022-05-31 Jason Teckoe Immediate release film coatings containing medium chain glycerides and substrates coated therewith
MX392182B (es) * 2015-03-13 2025-03-21 Esperion Therapeutics Inc Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Also Published As

Publication number Publication date
IL270866B2 (en) 2025-07-01
US20220249380A1 (en) 2022-08-11
KR20240130156A (ko) 2024-08-28
US20180338922A1 (en) 2018-11-29
PH12019502782A1 (en) 2020-10-26
IL270866B1 (en) 2025-03-01
JP7561814B2 (ja) 2024-10-04
UA126451C2 (uk) 2022-10-05
CN110996914A (zh) 2020-04-10
RU2019142143A3 (cg-RX-API-DMAC7.html) 2021-07-19
TW202400126A (zh) 2024-01-01
JP2020521763A (ja) 2020-07-27
KR20200032044A (ko) 2020-03-25
KR102830720B1 (ko) 2025-07-08
JP2024178341A (ja) 2024-12-24
TWI921644B (zh) 2026-04-11
AU2024204369B2 (en) 2025-09-11
BR112019024747A2 (pt) 2020-06-09
TW201900154A (zh) 2019-01-01
MX2023006541A (es) 2023-06-16
KR20250109242A (ko) 2025-07-16
AU2018272040A1 (en) 2019-12-19
IL318957A (en) 2025-04-01
RU2019142143A (ru) 2021-06-28
CA3064895A1 (en) 2018-11-29
EP3630070A1 (en) 2020-04-08
AU2024204369A1 (en) 2024-07-11
CL2019003437A1 (es) 2020-07-10
JP7187488B2 (ja) 2022-12-12
ZA201908030B (en) 2026-04-29
WO2018218147A1 (en) 2018-11-29
JP2023022224A (ja) 2023-02-14
IL270866A (en) 2020-01-30
KR102698987B1 (ko) 2024-08-28
TWI798228B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2023006541A (es) Formulaciones de dosis fija.
SA518391624B1 (ar) Ror- منظمات جاما
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
CL2020000747A1 (es) Formulaciones de niraparib.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
EA201790525A1 (ru) Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112017003346A2 (en) pyrazolopyridine derivatives, their uses, and pharmaceutical composition
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2021004566A (es) Compuestos terapeuticos.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos